| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 14-16% guided for FY27. |
|---|---|
| Margins | EBITDA growth of 25-30% expected for FY27. |
| Order book | 8-9 NCE molecules in pipeline; zero lost customer contracts. |
| Demand visibility | Normalizing customer ordering patterns; better visibility in Pharma. |
| Management confidence | High on US FDA remediation and Pharma/Animal Health recovery. |
Growth
Pharma revenue at Rs 233 Cr (EBIT 3.2%); Crop Protection at Rs 170 Cr (EBIT loss Rs 6 Cr).
Outlook
Full-year FY27 growth guided at 14-16% with 25-30% EBITDA growth. Animal Health target Rs 400 Cr+ by FY30.
Risks
Pricing pressure from China in Crop segment; ongoing US FDA remediation costs impacting current EBITDA margins.
Last quarter's promises, checked
Delivered
- Q4 EBITDA Margin 18-20% → delivered 20.3% (= BEAT)
- Debt-to-equity reduction → delivered 0.59 to 0.56 (= BEAT)
- Pharma utilization 75% → delivered 80-85% (= BEAT)
Partly delivered
- US FDA remediation timeline → ongoing CAPA completion (= PARTIAL)
- Animal Health scaling → validation complete, entering commercial phase (= PARTIAL)
Missed
- FY26 Pharma Growth 10% → delivered -1.5% YoY (= MISS)
- FY26 Crop Revenue Flat → delivered -16% YoY (= MISS)
- FY26 EBITDA Margin 18% → delivered 12.9% (= MISS)
Earnings Call Transcript filed with BSE, NSE: HIKAL. Summary written with AI assistance from the document.
Hikal Ltd: key numbers
- Share price
- ₹217.58
- Market cap
- ₹2,683 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -79.4×Sector 50.4×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 0.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Annual General Meeting
Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.
Hikal Production Started
Hikal has begun commercial production at its new cGMP Panoli facility, entering Personal Care manufacturing. First batches of UV filters and skincare ingredients are now being supplied to global customers.
Hikal Investor Presentation: Key Takeaways
Hikal reported Q1FY27 revenue of ₹403 Cr, up 6% YoY. Focus remains on pharma remediation and commissioning the Panoli facility for Personal Care.
Hikal Q1 FY27 Results: Net Loss of ₹7.4 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹402.8 Cr (+5.9% YoY) and a net loss of ₹7.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹7.4 Cr
Hikal Earnings Call: Key Takeaways
Q4FY26 revenue hit ₹519cr with 20.3% EBITDA margin. Management focuses on transition from remediation to sustainable technology-led growth despite US FDA and raw material headwinds.
Hikal Earnings Call: Key Takeaways
Hikal is navigating a difficult recovery phase, masked by a massive ₹47cr impairment and USFDA warning letter at Bangalore. While margins show sequential improvement, the core business remains stagnant and heavily reliant on regulatory resolution.